Cargando…

Alternative lengthening of human telomeres is a conservative DNA replication process with features of break‐induced replication

Human malignancies overcome replicative senescence either by activating the reverse‐transcriptase telomerase or by utilizing a homologous recombination‐based mechanism, referred to as alternative lengthening of telomeres (ALT). In budding yeast, ALT exhibits features of break‐induced replication (BI...

Descripción completa

Detalles Bibliográficos
Autores principales: Roumelioti, Fani‐Marlen, Sotiriou, Sotirios K, Katsini, Vasiliki, Chiourea, Maria, Halazonetis, Thanos D, Gagos, Sarantis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5167343/
https://www.ncbi.nlm.nih.gov/pubmed/27760777
http://dx.doi.org/10.15252/embr.201643169
Descripción
Sumario:Human malignancies overcome replicative senescence either by activating the reverse‐transcriptase telomerase or by utilizing a homologous recombination‐based mechanism, referred to as alternative lengthening of telomeres (ALT). In budding yeast, ALT exhibits features of break‐induced replication (BIR), a repair pathway for one‐ended DNA double‐strand breaks (DSBs) that requires the non‐essential subunit Pol32 of DNA polymerase delta and leads to conservative DNA replication. Here, we examined whether ALT in human cancers also exhibits features of BIR. A telomeric fluorescence in situ hybridization protocol involving three consecutive staining steps revealed the presence of conservatively replicated telomeric DNA in telomerase‐negative cancer cells. Furthermore, depletion of PolD3 or PolD4, two subunits of human DNA polymerase delta that are essential for BIR, reduced the frequency of conservatively replicated telomeric DNA ends and led to shorter telomeres and chromosome end‐to‐end fusions. Taken together, these results suggest that BIR is associated with conservative DNA replication in human cells and mediates ALT in cancer.